iBio (NYSEA:IBIO) announced a sixth amendment to its credit agreement with Woodforest National bank to allow sufficient time for the company to complete the pending sale of its cGMP biologics manufacturing facility. The...
Aurinia Pharmaceuticals (NASDAQ:AUPH) appointed Dr. Robert T. Foster, CEO of Hepion Pharmaceuticals, to its board. “As the doctor who discovered voclosporin, and Aurinia’s founder, [Dr. Foster] has a wealth of...
IntelGenx (TSX:IGX; OTCQB:IGXT) reported that it received the first purchase order (PO) for RIZAFILM from its U.S. commercial partner, Gensco Pharma. The company expects to ship the order to Gensco in the first quarter...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported that rencofilstat demonstrated anti-cancer activity across 86% of cancer types in a high-throughput screen on 850 cancer cell lines. At the Broad Institute of MIT and...
IntelGenx’s (TSX:IGX; OTCQB:IGXT) buprenorphine buccal film – for which an amendment to the abbreviated to new drug application (ANDA) requesting priority review has been filed by Chemo Research through its agent and...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported new research findings that discovered a mechanism by which the company’s lead drug candidate, rencofilstat, may exert anti-cancer activity. The research examined...
Anixa Biosciences (NASDAQ:ANIX) formed a cancer business advisory board (CBAB) with a roster of renowned cancer advocates, executives and physicians to guide the company’s clinical and business development...
Raymond James upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “strong buy” from “outperform” with a price target of $20.00, after pricing-in the TULSA-PRO system’s 2025 sales inflection. At mid-day on September 18...
Closely-held Mati Therapeutics completed a dedicated manufacturing facility for products formulated using the company’s Evolute sustained ocular drug delivery platform. Mati expects that the 10,000-square-foot facility...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of rencofilstat on lung tissue obtained from patients with idiopathic pulmonary fibrosis (IPF)...
Alliance Global Partners initiated coverage of Nano-X Imaging (NASDAQ:NNOX) with a “buy” rating and price target of $14.50. The stock closed at $7.66 on Sept. 7. “Nano-X’s novel digital X-ray source has the potential to...
OKYO Pharma (NASDAQ:OKYO) completed full enrollment of patients in the randomized portion of the Phase 2 clinical trial of topical ocular, OK-101, to treat dry eye disease (DED). A total of 240 patients were enrolled in...